ANI Stock Based Compensation To Revenue from 2010 to 2025
| ANIP Stock | USD 60.19 0.38 0.64% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.0488 | Current Value 0.0463 | Quarterly Volatility 0.66313339 |
Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 72.2 M, Interest Expense of 32.5 M or Selling General Administrative of 181.6 M, as well as many indicators such as Price To Sales Ratio of 2.23, Dividend Yield of 0.0012 or PTB Ratio of 2.37. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
ANI | Stock Based Compensation To Revenue |
Latest ANI Pharmaceuticals' Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of ANI Pharmaceuticals over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. ANI Pharmaceuticals' Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
ANI Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 0.23 | |
| Geometric Mean | 0.07 | |
| Coefficient Of Variation | 283.25 | |
| Mean Deviation | 0.32 | |
| Median | 0.05 | |
| Standard Deviation | 0.66 | |
| Sample Variance | 0.44 | |
| Range | 2.696 | |
| R-Value | (0.40) | |
| Mean Square Error | 0.40 | |
| R-Squared | 0.16 | |
| Significance | 0.12 | |
| Slope | (0.06) | |
| Total Sum of Squares | 6.60 |
ANI Stock Based Compensation To Revenue History
About ANI Pharmaceuticals Financial Statements
ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 0.05 | 0.05 |
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.